Why Diverse Clinical Trial Participation Matters
New England Journal of Medicine · 06.04.2023 · 388 (14) · 1252-1254
DOI: 10.1056/nejmp2215609 ↗Kurz gefasst
Fachartikel in der Zeitschrift New England Journal of Medicine, erschienen am 06.04.2023. Verfasst von Aaron L Schwartz und 3 weiteren Autor:innen. Beteiligte Einrichtung: From the Department of Medical Ethics and Health Policy (A.L.S., S.D.H.) and the Behavioral Economics to Transform Trial Enrollment Representativenes…. Hauptthemen laut MEDLINE: Motivation, Patient Participation, Clinical Trials as Topic, Diversity, Equity, Inclusion. Die Arbeit wurde bisher 225-mal zitiert (Crossref) und nennt 5 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- From the Department of Medical Ethics and Health Policy (A.L.S., S.D.H.) and the Behavioral Economics to Transform Trial Enrollment Representativeness (BETTER) Center (A.A.M., S.D.H.), Perelman School of Medicine, Unive…
ORCID-Profile: Marcella Alsan
Zitieren
APA
Schwartz, A. L., Alsan, M., Morris, A. A., & Halpern, S. D. (2023). Why Diverse Clinical Trial Participation Matters. New England Journal of Medicine, 388(14), 1252-1254. https://doi.org/10.1056/nejmp2215609
Vancouver
Schwartz AL, Alsan M, Morris AA, Halpern SD. Why Diverse Clinical Trial Participation Matters. New England Journal of Medicine. 2023;388(14):1252-1254. doi:10.1056/nejmp2215609
BibTeX
@article{Schwartz2023,
author = {Schwartz, Aaron L and Alsan, Marcella and Morris, Alanna A and Halpern, Scott D},
title = {Why Diverse Clinical Trial Participation Matters},
journal = {New England Journal of Medicine},
year = {2023},
volume = {388},
number = {14},
pages = {1252--1254},
doi = {10.1056/nejmp2215609}
}
EUVIMED